Role of lamivudine with transarterial chemoembolization in the survival of patients with hepatocellular carcinoma

Abstract

Lamivudine therapy could reduce HBV activation and improve survival of HCC patients treated with TACE. Lamivudine therapy and AFP level are two independent factors affecting OS.